Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 5/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11564188 | 0.75 | EPHX2 (0.48) | EPHX2FBP1CA1CA2KIF11 | |
| SCHEMBL3649476 | 0.75 | ALDH1A1 (0.55) | CA1CA2MAPK1CA12MMP2 | |
| SCHEMBL9217929 | 0.72 | EPHX2 (0.46) | EPHX2FBP1CA1CA2KIF11 | |
| SCHEMBL11406453 | 0.71 | KIF11 (0.48) | EPHX2CA1CA2KIF11CA12 | |
| Nitric Acid SCHEMBL20984887 | 0.70 | EPHX2 (0.48) | EPHX2FBP1CA1CA2KIF11 | |
| SCHEMBL16230308 | 0.70 | KIF11 (0.71) | CA1CA2KIF11MAPK1MAPT | |
| SCHEMBL29048919 | 0.70 | KIF11 (0.58) | CA1CA2KIF11MAPTCA9 | |
| SCHEMBL11414333 | 0.70 | KIF11 (0.47) | EPHX2CA1CA2KIF11CA12 | |
| SCHEMBL11416666 | 0.70 | KIF11 (0.52) | EPHX2CA1CA2KIF11CA12 | |
| SCHEMBL27859433 | 0.69 | KIF11 (0.47) | EPHX2CA1CA2KIF11CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488744-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070232617-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-7220763-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1551807-A4 | IMPROVED REAGENTS FOR N-AMINATION | SCIOS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1545528-A4 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1551807-A1 | IMPROVED REAGENTS FOR N-AMINATION | SCIOS INC. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1545528-A2 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050065344-A1 | Phenyl hydroxylamines containing one nitro and at least one trifluoromethyl substituent on the phenyl moiety; amination of indole | SCIOS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20040142940-A1 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004022712-A2 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004007462-A1 | IMPROVED REAGENTS FOR N-AMINATION | SCIOS INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142940-A1 | Indole-type derivatives as inhibitors of p38 kinase | MAPK1, MAPKAPK2, MAPK4 | EPHX2 4173/4885FBP1 3542/4885CA1 4167/4885 |
| US-20070232617-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | MAPK1, MAPKAPK2, MAPKAPK5 | EPHX2 4128/4885FBP1 3247/4885CA1 3942/4885 |
| US-20050065344-A1 | Phenyl hydroxylamines containing one nitro and at least one trifluoromethyl substituent on the phenyl moiety; amination of indole | NAT1, PNMT, HTR3A | EPHX2 3791/4885FBP1 3519/4885CA1 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.